Meeting
2013 ASCO Annual Meeting
A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).
Authors
Amar J. Gajjar
St. Jude Children's Research Hospital, Memphis, TN
Amar J. Gajjar , Sridharan Gururangan , Ibrahim A Qaddoumi , Roger Packer , Stewart Goldman , Michael Prados , Annick Desjardins , Maryam Fouladi , Naoko Takebe , Shaoyi Li , David W. Ellison , Tom Curran , Richard J. Gilbertson , James M. Boyett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00939484
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2035)
DOI
10.1200/jco.2013.31.15_suppl.2035
Abstract #
2035
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase II study of vismodegib in patients with SMO or PTCH1 mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
First Author: Anne S. Tsao
Poster
2020 ASCO Virtual Scientific Program
A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients.
First Author: Wim van Boxtel
Poster
2017 ASCO Annual Meeting
Targeted therapy for advanced salivary cancer with HER2 or hedgehog alterations: Interim data from MyPathway.
First Author: Razelle Kurzrock
Poster
2016 ASCO Annual Meeting
MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.
First Author: Didier Frappaz